✦ LIBER ✦

The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide

✍ Scribed by Wang, Tzu-Fei; Ahluwalia, Rohan; Fiala, Mark A.; Trinkaus, Kathryn M.; Cox, Doug P.; Jaenicke, Matthew; Moliske, Caitlin C.; Carson, Kenneth R.; Wildes, Tanya M.; Tomasson, Michael H.; Stockerl-Goldstein, Keith E.; Vij, Ravi

Book ID: 121297034
Publisher: Informa plc
Year: 2013
Tongue: English
Weight: 209 KB
Volume: 55
Category: Article
ISSN: 1042-8194
DOI: 10.3109/10428194.2013.803547

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of patients with relapsed/refr

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

✍ Dimopoulos, M A; Kastritis, E; Christoulas, D; Migkou, M; Gavriatopoulou, M; Gko 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 473 KB

The efficacy and safety of lenalidomide

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

✍ Meletios Dimopoulos; Adrian Alegre; Edward A. Stadtmauer; Hartmut Goldschmidt; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

Incidence of extramedullary disease in p

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

✍ Short, K Detweiler; Rajkumar, S V; Larson, D; Buadi, F; Hayman, S; Dispenzieri, 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 163 KB

Impact of genomic aberrations including

Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone

✍ Chang, Hong; Jiang, Allan; Qi, Connie; Trieu, Young; Chen, Christine; Reece, Don 📂 Article 📅 2010 🏛 Informa plc 🌐 English ⚖ 767 KB

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

Dickkopf-1 and sclerostin in different p

Dickkopf-1 and sclerostin in different phases of multiple myeloma; The effect of lenalidomide and dexamethasone treatment with or without bortezomib

✍ E. Terpos; D. Christoulas; M. Gkotzamanidou; C. Bratengeier; M. Gavriatopoulou; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 67 KB